Related references
Note: Only part of the references are listed.Development and evaluation of Eudragit coated environmental sensitive solid lipid nanoparticles using central composite design module for enhancement of oral bioavailability of linagliptin
D. Krishna Veni et al.
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS (2020)
Lamotrigine loaded poly-ε-(D,L-lactide-co-caprolactone) nanoparticles as brain delivery system
Hussein O. Ammar et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Inflammasomes and type 2 diabetes: An updated systematic review
Zahra Sepehri et al.
IMMUNOLOGY LETTERS (2017)
Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid cleavable lipid
Rahul S. Kalhapure et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Evaluation of current trends and recent development in insulin therapy for management of diabetes mellitus
Muhammad Sarfraz Nawaz et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
A pH-sensitive methenamine mandelate-loaded nanoparticle induces DNA damage and apoptosis of cancer cells
Linhua Zhang et al.
ACTA BIOMATERIALIA (2017)
Formulation and in vitro evaluation of polymeric enteric nanoparticles as dermal carriers with pH-dependent targeting potential
Fitsum Feleke Sahle et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study
Abeer Hanafy et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2016)
Amorphous polymeric binary blend pH-responsive nanoparticles for dissolution enhancement of antiviral drug
Deep R. Naik et al.
JOURNAL OF SAUDI CHEMICAL SOCIETY (2016)
Assessing the In Vitro Drug Release from Lipid-Core Nanocapsules: a New Strategy Combining Dialysis Sac and a Continuous-Flow System
Diego Fontana de Andrade et al.
AAPS PHARMSCITECH (2015)
AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015
Alan J. Garber et al.
ENDOCRINE PRACTICE (2015)
Protein-Functionalized PLGA Nanoparticles of Lamotrigine for Neuropathic Pain Management
Jigar Lalani et al.
AAPS PHARMSCITECH (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy
Tausif Alam et al.
EXPERT OPINION ON DRUG DELIVERY (2015)
Statistical modeling of zaltoprofen loaded biopolymeric nanoparticles: Characterization and anti-inflammatory activity of nanoparticles loaded gel
Hirva A. Shah et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION (2015)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Michael Lehrke et al.
CLINICAL THERAPEUTICS (2014)
Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride
Rekha Khaira et al.
SCIENTIFIC WORLD JOURNAL (2014)
In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes
Lejiao Jia et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel
Saeed Manoochehri et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Andrew J. Lewin et al.
CLINICAL THERAPEUTICS (2012)
Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system
Shailesh S. Chalikwar et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2012)
Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial
Stuart A. Ross et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
A. J. Scheen
DIABETES & METABOLISM (2012)
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
T. Haak et al.
DIABETES OBESITY & METABOLISM (2012)
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
R. Kawamori et al.
DIABETES OBESITY & METABOLISM (2012)
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension
A. H. Barnett et al.
DIABETES OBESITY & METABOLISM (2012)
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux
Holger Fuchs et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Coexisted components of Salvia miltiorrhiza enhance intestinal absorption of cryptotanshinone via inhibition of the intestinal P-gp
Haixue Dai et al.
PHYTOMEDICINE (2012)
Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo
X. F. Wang et al.
VETERINARY JOURNAL (2012)
Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies
U. Seju et al.
ACTA BIOMATERIALIA (2011)
Effect of Pluronic P123 and F127 Block Copolymer on P-glycoprotein Transport and CYP3A Metabolism
Yanbin Guan et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
R. Gomis et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting
M. R. Aji Alex et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
T. Forst et al.
DIABETIC MEDICINE (2010)
Preparation and characterization of silybin-loaded nanostructured lipid carriers
Le-Jiao Jia et al.
DRUG DELIVERY (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats
Zhiwen Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Advances in polymeric micelles for drug delivery and tumor targeting
Uttam Kedar et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2010)
Effect of nanoparticle concentration on zeta-potential measurement results and reproducibility
Ratna Tantra et al.
PARTICUOLOGY (2010)
Binding to Dipeptidyl Peptidase-4 Determines the Disposition of Linagliptin (BI 1356) - Investigations in DPP-4 Deficient and Wildtype Rats
Silke Retlich et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2009)
Tissue Distribution of the Novel DPP-4 Inhibitor BI 1356 is Dominated by Saturable Binding to its Target in Rats
Holger Fuchs et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin
Robhash Kusam Subedi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
Holger Fuchs et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2009)
Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies
C. Han et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2009)
Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
Nancy Bohannon
POSTGRADUATE MEDICINE (2009)
Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles
ShuYu Xie et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2008)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Huettner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Gliptins: a new class of oral hypoglycaemic agent
H. Chahal et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2007)
Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers
Ina Hubatsch et al.
NATURE PROTOCOLS (2007)
Oral bioavailability of cyclosporine:: Solid lipid nanoparticles (SLN®) versus drug nanocrystals
R. H. Mueller et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery
DH Kim et al.
BIOMATERIALS (2006)
Oral solid lipid nanoparticle-based antitubercular chemotherapy
R Pandey et al.
TUBERCULOSIS (2005)
Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles
V Venkateswarlu et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics
N Hussain et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man
L Salphati et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2001)
Solid lipid nanoparticles -: Production, characterization and applications
W Mehnert et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art
RH Müller et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2000)
Share Paper
